Impaired plasmacytoid dendritic cell maturation and differential chemotaxis in chronic hepatitis C virus: associations with antiviral treatment outcomes
OPEN ACCESS- J A Mengshol1,
- L Golden-Mason1,2,
- N Castelblanco1,
- K A Im3,
- S M Dillon4,5,
- C C Wilson4,5,
- H R Rosen1,2
- 1Division of Gastroenterology and Hepatology, Department of Medicine, University of Colorado Denver, Colorado, USA
- 2Integrated Program in Immunology and Hepatitis C Research Center, Denver, Colorado, USA
- 3Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Phildelphia, USA
- 4Division of Infectious Diseases, Department of Medicine, University of Colorado, Denver, Colorado, USA
- 5Division of Clinical Immunology, Department of Medicine, University of Colorado, Denver, Colorado, USA
- Dr H R Rosen, GI and Hepatology Division, B-158, Academic Office Building 1, 12631 East 17th Avenue, Room 7614, PO Box 6511, Aurora, CO 80045, USA; hugo.rosen{at}ucdenver.edu
- Revised 24 November 2008
- Accepted 11 December 2008
Abstract
Background: Dendritic cell (DC) defects may contribute to chronicity in hepatitis C virus (HCV) infection and determine response to PEG–interferon and ribavirin therapy via poor T cell stimulation. Studies to date have produced inconsistent results regarding DC maturation and function: no large study has examined DCs before and after therapy.
Aims: We examined if DC defects in maturation and chemotaxis are present by comparing therapeutic responders to non-responders.
Methods: We analysed peripheral DCs of 64 HCV genotype 1-infected patients from the Virahep-C study 2 weeks before and 24 weeks after therapy. We used flow cytometry to enumerate plasmacytoid DC (pDC) and myeloid DCs (mDC) and quantify expression of chemokine receptors and maturation markers. Chemotaxis was measured with an in vitro assay.
Results: Pre-treatment frequencies of pDCs and mDCs were significantly lower in HCV patients than controls and successful therapy normalised pDCs. Levels of CXCR3 and CXCR4 on pDCs were higher at baseline compared to normal controls and decreased with therapy. Pre-therapy levels of co-stimulatory marker CD40 and the maturation marker CD83 were higher in pDCs of patients chronically infected with HCV compared to normal patients, and levels of both markers dropped significantly with therapy in the SVR+ group only. Other maturation markers (CD86 and CCR7) were not elevated suggesting a partially activated phenotype. Baseline chemotaxis of pDCs to CXCL12 and CXCL10 predicted failure of antiviral response and correlated with the histological activity index inflammation score.
Conclusions: Plasmacytoid DC defects exist in chronic HCV and successful antiviral therapy normalises many phenotypic and functional abnormalities.
Footnotes
-
Funding: JAM is supported by T32 DK7038-32. This work is supported by RO1 DK071560 (to HRR). This study was funded as a cooperative agreement by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the Intramural Research Program of the National Cancer Institute (NCI) with further support under a Cooperative Research and Development Agreement (CRADA) with Roche Laboratories, Inc. A complete listing of participants in the Virahep-C study is given in reference 37. Grant numbers: U01 DK60329, U01 DK60340, U01 DK60324, U01 DK60344, U01 DK60327, U01 DK60335, U01 DK60352, U01 DK60342, U01 DK60345, U01 DK60309, U01 DK60346, U01 DK60349, U01 DK60341.
-
Competing interests: None.
-
Ethics approval: The protocol and consent form were approved by the institutional review boards of the participating institutions. All patients gave informed, written consent. The clinical trial has already been published in reference 37.
